Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosbretabulin - Mateon Therapeutics

Drug Profile

Fosbretabulin - Mateon Therapeutics

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Mateon Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); OXiGENE; University of Aarhus; University of Florida; University of Kentucky
  • Class Antineoplastics; Combretastatins; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioma; Thyroid cancer; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Age-related macular degeneration; Colorectal cancer; Diabetic retinopathy; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leukaemia; Malignant carcinoid syndrome; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Polypoidal choroidal vasculopathy; Psoriasis; Rheumatoid arthritis; Thyroid cancer

Most Recent Events

  • 19 Oct 2018 Safety and efficacy data from a phase Ib/II trial in Ovarian cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 14 Aug 2018 Mateon Therapeutics plans a phase IIa trial for Malignant melanoma (Late-stage disease, Combination therapy)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top